Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | XXII 0.1977 -8.34% | SHFS 0.1324 -61.39% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | YFOR 0.2236 -1.58% | RBNE 0.19 -2.56% | TQQQ 66.29 -0.20% | VZ 44.66 -1.19% | TSLL 9.76 -1.21% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | SQQQ 39.68 0.20% | AIOK 12.02 182.82% | ONDS 6.2 2.99% | AAPL 347.725 -0.14% | LABT 0.31 -36.67% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | GRAB 2.79 -2.11% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | IREN 24.905 -2.37% | QID 14.55 0.14% | RKT 11.73 -0.09% | WULF 11.32 0.00% | BE 193.3 -11.24%
VIVivoSim Labs, Inc. logo

VivoSim Labs, Inc. (VIVS)

NASDAQ · Currency in USD
$0.15 ▼ -0.01 (-6.84%)
At close: Oct 23, 4:00 PM ET. Market closed.
$0.15 ▲ +0.00 (+1.01%)
After hours: Oct 23, 7:32 PM ET

Summary

Previous Close
$0.16
Open
$0.15
Day's Range
$0.14 – $0.16
52 Week Range
$0.14 – $3.40
Volume
744,692
Avg. Volume
4,272,652
Market Cap
$2.46M
Beta (5Y Monthly)
1.49
PE Ratio (TTM)
--
EPS (TTM)
-$2.35
Earnings Date
Nov 5, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
--

Profile: VivoSim Labs, Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
15
CEO
Keith Murphy
Website
vivosim.ai

VivoSim Labs, Inc., a pharmaceutical and biotechnology services company, provides testing of drugs and drug candidates in three-dimensional (3D) human tissue models of liver and intestine. It offers partners liver and intestinal toxicology insights through its new approach methodologies (NAM) models; and bespoke services in the areas of investigational toxicology, mechanism of drug action elucidation, and other applications of complex human tissue models. The company also provides liver toxicology predictive screening and research services, as well as works on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at various stages of drug development; and uses its proprietary technologies to build functional 3D human tissues that mimic key aspects of native human tissue composition, architecture, function, and disease.

Earnings

Next report: Thu, Nov 5, 2026
DateEst.Actual
Aug 12, 2026–-$0.25
Jul 14, 2026-$2.04-$2.21Miss
Feb 11, 2026-$2.40-$1.03Beat
Nov 6, 2025-$2.28-$0.98Beat
Aug 12, 2025–-$1.14
May 30, 2025-$2.28-$3.48Miss

Get free alerts on VIVS and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.